NASDAQ | VICL: 1.02  +0.01


Peripheral arterial disease (PAD) is characterized by a reduction in blood flow to tissues outside of the heart, most commonly the lower leg, and usually is the result of atherosclerosis (the buildup of fatty deposits in arteries). Reduced blood flow leads to a decline in the health and functioning of the affected tissues. In the more severe form of critical limb ischemia (CLI), reduced transport of oxygen to tissues results in limb necrosis (ulcers and gangrene) and pain at rest.

PAD affects an estimated 8 million Americans (up to 20% of Americans aged 65 or older), and 35% of PAD patients experience hospitalization within 9 months of diagnosis. The yearly incidence of CLI is estimated at 125,000 to 250,000 US patients per year; 1-year mortality is 25%, but rises to 45% in the 40% of CLI patients whose only treatment option is major limb amputation.

Vical believes that its pDNA delivery technology represents the promise for new therapies for PAD. Delivering plasmids which encode growth factor proteins has been well documented to induce the growth and development of new blood vessels, a process known as angiogenesis. As a result, blood flow can be restored, rescuing tissues from the risk of ischemic damage and death.

P. 858 646 1100 10390 Pacific Center Court, San Diego, California 92121
Designed by Mentus
This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.